Contact Marin & Murphy

Marin & Murphy is licensed in South Carolina, Massachusetts, Rhode Island, and Connecticut, and works with lawyers licensed across the country.

Marin & Murphy is not licensed in Georgia; a matter there would be handled with, or referred to, a lawyer licensed in that state.

Super Lawyers® 2014–2024(888) 348-2735

Dupixent — CTCL Litigation

The Dupixent Litigation, Explained

Federal cases are consolidated in MDL 3180, most cases are in their earliest stages, and no settlement exists. Here is what is publicly known.

ACTIVE LITIGATION — NO SETTLEMENT. MDL 3180 underway · deadlines vary by state.

Marin & Murphy is not licensed in Georgia; details below.

Attorneys Stefanie A. Murphy and Matthew T. Marin of Marin & Murphy Law Firm

Partners

Stefanie A. Murphy & Matthew T. Marin

Super Lawyers® honorees · members of the American Association for Justice · concentrating in personal injury and mass-tort litigation.

No settlement has been reached in the Dupixent litigation, and most cases are in their earliest stages. Every case must be proven on its own facts. Whether any patient has a claim depends on the facts and the law of their state. The information below covers the litigation itself.

Marin & Murphy Law Firm is not licensed in Georgia; details below.

For readers in Georgia the essentials are the same: plaintiffs allege an association between Dupixent (dupilumab) and cutaneous T-cell lymphoma, no court has found Dupixent causes CTCL, and no settlement exists. Whether any individual has a claim depends on their medical records and the law of their state. The information below covers the litigation itself.

Where Things Stand in the Dupixent CTCL Litigation

Made by Sanofi and Regeneron and prescribed in Georgia as it is across the country, Dupixent (dupilumab) is a prescription biologic, FDA-approved since March 2017, now carrying nine indications, including atopic dermatitis, asthma, and COPD. In June 2026 — the date that governs Georgia cases too — the Judicial Panel on Multidistrict Litigation centralized the pending federal cases as MDL 3180 in the United States District Court for the District of New Jersey, before Judge Zahid N. Quraishi. The complaints in the consolidated Dupixent lawsuit allege that the drug is associated with an increased risk of cutaneous T-cell lymphoma (CTCL) and that the manufacturers failed to warn patients and doctors. As of November 2, 2026, 40 cases were pending in the MDL that would govern any filing from Georgia; the current count and its method are kept on the MDL 3180 tracker. No merits ruling exists anywhere, Georgia included, and neither does any settlement.

What the Filings Allege — and What They Do Not

For readers in Georgia: what is alleged is an association, and nothing has been adjudicated. Published studies report a statistical association between dupilumab and CTCL — an association the study authors themselves note does not establish causation — and the FDA has identified a potential safety signal for CTCL that it is still evaluating. No lymphoma or malignancy warning appears on Dupixent’s current label, in Georgia or anywhere else. The FDA adverse event reports connected to this question are agency reports, not verified causes, and the courts have decided nothing on the merits — in Georgia or anywhere else.

Georgia Residents in the Dupixent MDL: Six Docketed Cases

Georgia has more Dupixent CTCL filings than any other state on the public record. A Georgia resident filed Street v. Regeneron Pharmaceuticals, Inc. in the Northern District of Georgia on January 27, 2026 (No. 1:26-cv-00493, public docket), alleging Dupixent injections from May to September 2023 followed by a diagnosis of both mycosis fungoides and Sézary syndrome first made in September 2023; the complaint names Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC and includes a spouse’s loss-of-consortium claim. Five additional Georgia-resident cases are docketed on the same track — Nalls, Long, Seals, Oakley, and Henry — all filed in the Northern District of Georgia between December 2025 and April 2026 and now proceeding in MDL 3180 in the District of New Jersey. Three of the six plead both mycosis fungoides and Sézary syndrome, two plead mycosis fungoides, and one pleads cutaneous T-cell lymphoma. These are allegations from a complaint; no court has ruled on them, and no settlement exists.

Who the Filed Cases Include

The consolidated cases — whether from Georgia or elsewhere — involve people who used Dupixent and were diagnosed with cutaneous T-cell lymphoma or a related T-cell lymphoma subtype during or after that use. The claims carry no minimum-use requirement, and in Georgia, estates of patients who have died may bring claims under state wrongful-death and survival statutes. Whether any individual’s circumstances resemble the filed cases is a question of medical records and state law, not of headlines — and for a Georgia resident, it is a question for an attorney licensed in Georgia.

Georgia’s Federal Courts and the Path to MDL 3180

Georgia is served by three federal district courts: the United States District Court for the Northern District of Georgia; the United States District Court for the Middle District of Georgia; and the United States District Court for the Southern District of Georgia. No Dupixent CTCL lawsuit filed there proceeds alone — the Judicial Panel on Multidistrict Litigation has centralized these cases as MDL 3180 before Judge Zahid N. Quraishi in the United States District Court for the District of New Jersey, so a Georgia case is transferred to the MDL for coordinated pretrial proceedings — or, where the MDL court’s case-management orders permit, filed in the District of New Jersey directly. Either route leads to the same consolidated proceeding, and a case from Georgia remains an individual claim; an MDL is not a class action.

Filing Deadlines Under Georgia Law

Georgia’s general statute of limitations for personal-injury claims is two years under O.C.G.A. § 9-3-33. Georgia generally accrues a personal-injury claim at the time of injury; a discovery rule is recognized for continuing-tort and latent-disease claims but not for discrete-injury claims. How a limitations period applies to any specific CTCL diagnosis depends on the dates in the medical records, the legal theory pleaded, and Georgia tolling and accrual doctrine. An attorney licensed in Georgia can evaluate whether a claim is timely.

A wrongful-death claim carries a two-year period that begins at death (O.C.G.A. § 9-3-33), brought by the surviving family members entitled by statute.

How Common Is CTCL in Georgia?

Georgia is home to about 11.2 million people (U.S. Census Bureau, 2024 estimate). Cutaneous T-cell lymphoma is rare — roughly 8.55 new cases per million person-years (SEER) — which works out to on the order of 95 new CTCL diagnoses across Georgia in a typical year. Rarity means the numbers on this page cannot answer an individual question — in Georgia, any one claim is decided by medical records read against state law.

About Marin & Murphy Law Firm and Georgia

Marin & Murphy Law Firm is a personal-injury and mass-tort law firm; its attorneys’ individual admissions are listed at the bottom of this page, and this page is published as litigation information. Marin & Murphy Law Firm is not licensed in Georgia. The firm does not accept Georgia legal matters; inquiries from Georgia residents are referred to attorneys licensed in Georgia. Some matters may be referred to other lawyers. An attorney licensed in Georgia can evaluate whether a claim is timely and how Georgia law applies to a particular diagnosis.

Georgia Dupixent Litigation FAQs

Are there Dupixent lawsuits in Georgia courts?

Rather than proceeding separately around the country, the federal cases — filings from Georgia included — are consolidated in MDL 3180 in the District of New Jersey. A Dupixent CTCL case filed in a Georgia federal court is subject to transfer into that consolidated proceeding. This page does not track filings outside the federal system.

Who is included in the filed cases?

People — from Georgia or anywhere — who used Dupixent and were diagnosed with cutaneous T-cell lymphoma or a related T-cell lymphoma subtype during or after that use. There is no minimum-use requirement, and estates of patients who have died — in Georgia as elsewhere — bring claims under state wrongful-death and survival statutes.

Has any court found that Dupixent causes CTCL?

No. Plaintiffs allege an association; published studies report a statistical association that their authors note does not establish causation; the FDA is still evaluating a potential safety signal; and the Dupixent label — the same one dispensed in Georgia — currently contains no lymphoma warning.

Is there a Dupixent settlement?

No. No settlement exists and no court has ruled on the merits — the litigation, claims from Georgia included, is in its earliest stages. A number implying otherwise, wherever a reader in Georgia saw it, did not come from the docket.

What is the filing deadline for a Georgia Dupixent claim?

Filing deadlines come from Georgia statutes and court doctrine, and more than one rule can bear on when the period begins to run; the section above covers what is settled and what is not. An attorney licensed in Georgia can evaluate whether a claim is timely.

Does Marin & Murphy Law Firm accept Georgia cases?

No. Marin & Murphy Law Firm is not licensed in Georgia and does not accept Georgia legal matters; inquiries from Georgia residents are referred to attorneys licensed in Georgia.

Georgia Dupixent Prescribing: The Publicly Reported Numbers

Dupixent (dupilumab) is widely prescribed in Georgia, most often for atopic dermatitis and other inflammatory conditions. Federal drug-utilization data gives a state-level picture of how commonly the medication is used:

20,807Dupixent prescriptions reported by Medicaid in Georgia in 2025
17,715Dupixent prescriptions reported by Medicaid in Georgia in 2024
4Schedule A actions in MDL 3180 were filed in Georgia federal courts before transfer

Georgia saw its reported Medicaid prescription count grow by about 17% between 2024 and 2025. In 2025, Medicaid reimbursement for Dupixent in Georgia totaled $84.2 million. These figures cover Medicaid outpatient utilization only — they do not include prescriptions paid through Medicare or private insurance, so the total number of residents of Georgia using Dupixent is higher. Totals exclude a small number of records the program suppresses for privacy.

When the federal Judicial Panel on Multidistrict Litigation centralized the Dupixent lawsuits on June 4, 2026, 4 of the 15 actions listed on the transfer order’s Schedule A were filed in Georgia federal courts before transfer to MDL 3180 in the District of New Jersey.

Sources: Centers for Medicare & Medicaid Services, State Drug Utilization Data 2024 and 2025 (accessed August 21, 2026); In re: Dupixent (Dupilumab) Products Liability Litigation, MDL No. 3180, JPML Transfer Order, Schedule A (June 4, 2026). Utilization data reflects prescriptions reported by state Medicaid programs and is not evidence that any individual prescription caused injury.

Sources
  • U.S. Judicial Panel on Multidistrict Litigation, Pending MDL Dockets by MDL Number (November 2, 2026) — jpml.uscourts.gov
  • MDL 3180 docket records — CourtListener dockets 72288297 (JPML) and 73443394 (D.N.J. 3:26-md-03180), reviewed September 15, 2026.
  • O.C.G.A. § 9-3-33 — Georgia statute of limitations discussed above.
  • U.S. Census Bureau, Vintage 2024 Population Estimates (NST-EST2024), resident population as of July 1, 2024.
  • SEER program data: cutaneous T-cell lymphoma incidence ≈8.55 cases per million person-years.

Where we practice

Marin & Murphy Law Firm is a national mass tort and personal injury law firm with offices in Rhode Island, Connecticut and South Carolina, representing injured people and families nationwide. Where a matter arises in a state in which our attorneys are not admitted, we work with lawyers licensed in that state. We are not licensed in Georgia. The firm does not accept Georgia legal matters; inquiries from Georgia residents are referred to attorneys licensed in Georgia. This page is attorney advertising and is provided for general information; it is not legal advice, and reading it does not create an attorney–client relationship.